Editorial Commentary: Top Five Stories of the Cellular Landscape and Therapies of Atherosclerosis: Current Knowledge and Future Perspectives

References

[1] Wang Z, Ma L, Liu M, et al. Writing Committee of the Report on Cardiovascular Health and Diseases in China. Summary of the 2022 report on cardiovascular health and diseases in China. Chin Med J (Engl), 2023, Nov. 28. doi: https://doi.org/10.1097/CM9.0000000000002927.

[2] RothGA, MensahGA, JohnsonCOGBD-NHLBIJACC Global Burden of Cardiovascular Diseases Writing Group, et al.. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol, 2020, 76(25): 2982-3021

[3] Pan Q, Chen C, Yang YJ. Top five stories of the cellular landscape and therapies of atherosclerosis: current knowledge and future perspectives. Curr Med Sci, 2023, Dec. 7. doi: https://doi.org/10.1007/s11596-023-2818-2. Online ahead of print.

[4] LiuC, LiZ, LiB, et al.. Relationship between ferroptosis and mitophagy in cardiac ischemia reperfusion injury: a mini-review. PeerJ, 2023, 11: e14952

[5] HeX, FanX, BaiB, et al.. Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. Pharmacol Res, 2021, 165: 105447

[6] TaoX, WanX, WuD, et al.. A tandem activation of NLRP3 inflammasome induced by copper oxide nanoparticles and dissolved copper ion in J774A.1 macrophage. J Hazard Mater, 2021, 411: 125134

[7] RidkerPM. From CANTOS to CIRT to COLCOT to Clinic: Will All Atherosclerosis Patients Soon Be Treated With Combination Lipid-Lowering and Inflammation-Inhibiting Agents?. Circulation, 2020, 141(10): 787-789

[8] YangM, LvH, LiuQ, et al.. Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway. Oxid Med Cell Longev, 2020, 2020: 9173530

[9] ZhangFS, HeQZ, QinCH, et al.. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol Sin, 2022, 43(9): 2173-2190

[10] HanssonGK, LibbyP, TabasI. Inflammation and plaque vulnerability. J Intern Med, 2015, 278(5): 483-493

[11] SinglaB, LinHP, AhnW, et al.. Loss of myeloid cell-specific SIRPα, but not CD47, attenuates inflammation and suppresses atherosclerosis. Cardiovasc Res, 2022, 118(15): 3097-3111

[12] AzcutiaV, RoutledgeM, WilliamsMR, et al.. CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions. Mol Biol Cell, 2013, 24(21): 3358-3368

[13] KojimaY, VolkmerJP, McKennaK, et al.. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature, 2016, 536(7614): 86-90

[14] DöringY, SoehnleinO, WeberC. Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis. Circ Res, 2017, 120(4): 736-743

[15] VaidyaK, TuckerB, KurupR, et al.. Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. J Am Heart Assoc, 2021, 10(1): e018993

[16] LiberaleL, HolyEW, AkhmedovA, et al.. Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. J Clin Med, 2019, 8(12): 2072

[17] GomezD, OwensGK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res, 2012, 95(2): 156-164

[18] OrrAW, LeeMY, LemmonJA, et al.. Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol, 2009, 29(2): 225-231

[19] BhaskarV, YinJ, MirzaAM, et al.. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis, 2011, 216(2): 313-320

[20] LaeraN, MalerbaP, VacantiG, et al.. Impact of Immunity on Coronary Artery Disease: An Updated Pathogenic Interplay and Potential Therapeutic Strategies. Life (Basel), 2023, 13(11): 2128

[21] WangSS, HuSW, ZhangQH, et al.. Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties. PLoS One, 2015, 10(8): e0136026

[22] FrodermannV, van DuijnJ, van PelM, et al.. Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development. Sci Rep, 2015, 5: 15559

[23] MuY, XuW, LiuJ, et al.. Mesenchymal stem cells moderate experimental autoimmune uveitis by dynamic regulating Th17 and Breg cells response. J Tissue Eng Regen Med, 2022, 16(1): 26-35

[24] LiJZ, CaoTH, HanJC, et al.. Comparison of adipose- and bone marrow-derived stem cells in protecting against ox-LDL-induced inflammation in M1-macrophage-derived foam cells. Mol Med Rep, 2019, 19(4): 2660-2670

[25] SagerHB, DuttaP, DahlmanJE, et al.. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med, 2016, 8(342): 342ra80

[26] NakashiroS, MatobaT, UmezuR, et al.. Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE−/− Mice. Arterioscler Thromb Vasc Biol, 2016, 36(3): 491-500

[27] TangJ, LiT, XiongX, et al.. Colchicine delivered by a novel nanoparticle platform alleviates atherosclerosis by targeted inhibition of NF-κB/NLRP3 pathways in inflammatory endothelial cells. J Nanobiotechnology, 2023, 21(1): 460

[28] LiY, CheJ, ChangL, et al.. CD47- and Integrin α4/βl-Comodified-Macrophage-Membrane-Coated Nanoparticles Enable Delivery of Colchicine to Atherosclerotic Plaque. Adv Healthc Mater, 2022, 11(4): e2101788